Furthermore, both navitoclax and the A-1331852 BCL-xL inhibitor induce apoptotic death in PDGF-activated hepatic fibroblast and in vivo reduce liver fibrosis in the MDR2−/− mouse model [49], supporting a link between BH3-induced apoptosis and liver fibrogenesis [50]. Here, BCL2L1 is linked to Hepatic fibrosis.